NCT07655115: Single Dose Double-blind, Placebo-controlled Cross-over (SDDBPCCO) Shiftability Study, Will be Followed by a 10-week Open-label Study With Arbaclofen (4 Weeks of Titration and Then 6 Weeks of Active/Stable Treatment). The Effects of Arbaclofen on Target EEG and ERG Metrics Will be Associated With th
- State
- Under way
- Phase
- Phase 3
- People
- 103 planned
- Started
- 20 Nov 2025
- Primary completion
- 31 Dec 2026
- Arms
- arbaclofen
- Results
- None posted
- 20 Nov 2025: Trial started
- 17 Jun 2026: Trial registered